Filtered By:
Condition: Thrombosis
Management: Budgets

This page shows you your search results in order of date.

Order by Relevance | Date

Total 2 results found since Jan 2013.

APSC2015-1220 Budget Impact of Ticagrelor as Compared to Older Oral Anti-Platelet Drugs: An Indian Perspective
Ticagrelor is a P2Y12 inhibitor indicated to reduce the rate of thrombotic cardiovascular (CV) events in patients with acute coronary syndrome (ACS). In PLATO study, Ticagrelor has shown to reduce the rate of a combined endpoint of CV death, MI or stroke, rate of stent thrombosis compared to clopidogrel. As of Clopidogrel, the price of Ticagrelor is higher, but the benefits derived are significant. There is a need for budget impact analysis of Ticagrelor comparing with Clopidogrel in developing countries like India.
Source: CVD Prevention and Control - April 27, 2015 Category: Cardiology Authors: Gopinath Nageshwaran, Pawan Bhati, Alap Gandhi, Dinesh Chakraborty, Ammar Raza, Bhavesh Kotak Tags: Poster Abstract Source Type: research

Budget Impact of Left Atrial Appendage Occulusion in Patients with Atrial Fibrillation Contraindicated to Anticoagulation
Stroke is a leading public health problem in terms of mortality and economic burden in Korea. Anticoagulants are the mainstay for ischemic stroke prevention in atrial fibrillation (AF), but many patients have contraindications to these drugs. A number of catheter-based left atrial appendage occlusion (LAAO) devices devised to eliminate the major cause of thromboembolism in AF patients have been commercialized in Europe but are not yet available in Korea. The purpose of this study is to perform a budget impact analysis of LAAO in patients with AF contraindicated to anticoagulation.
Source: Value in Health - November 1, 2014 Category: Global & Universal Authors: J.W. Park, M. Koullick, E. Han Tags: CARDIOVASCULAR DISORDERS - Cost Studies Source Type: research